Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Moderna has been added to the Nasdaq-100 index following a 700% stock surge this year, driven by FDA approvals of updated COVID-19 and flu vaccines, as well as promising phase 3 trial results for its cancer vaccine candidate. The inclusion will increase institutional ownership and potentially raise the stock price, though investors should focus on the company's future potential with its cancer vaccine pipeline.